Skip to content

Effect of erioperative based-AVNS nutritional trategy on accelerated recovery and long-term prognosis of hip fracture: a single-center, prospective randomized controlled trials

Effect of erioperative based-AVNS nutritional trategy on accelerated recovery and long-term prognosis of hip fracture: a single-center, prospective randomized controlled trials

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115030
Enrollment
Unknown
Registered
2025-12-22
Start date
2025-09-22
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip fracture

Interventions

Trial group:Ultrasound-guided fascia iliaca block(0.33%Ropivacaine) Parecoxib sodium 40 mg iv Dexamethasone 10mg Ondansetron 4mg Nutritional supplements (from the day before surgery until hospitalizat
Control group:General management plan

Sponsors

Affiliated hospital of chengdu university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 50–90 years (age selection based on previous research foundation, NRS-2002 nutritional assessment criteria, and references); 2. Presence of nutritional risk upon admission, defined as NRS-2002 score >=3; 3.ASA classification II–III; 4. No history of severe drug allergies (Ropivacaine, Sufentanil, Parecoxib Sodium, Ondansetron, Dexmedetomidine, Pantoprazole, Lidocaine, etc.).

Exclusion criteria

Exclusion criteria: 1. Reoperation or other surgical procedures during the same hospitalization; 2. Severe abnormalities in hepatic, renal, cardiopulmonary, or coagulation function; 3. Preoperative admission to the ICU; 4. Patients who received blood product transfusions preoperatively; 5. Patients who received preoperative enteral or parenteral nutrition therapy; 6. Pathological fractures ( due to bone tumors, metastatic bone disease, etc.); 7. Pre-existing immune or severe metabolic diseases ( active tuberculosis, malignant tumors, severe diabetes with complications, etc.); 8. Allergic predisposition, including a history of severe drug allergies ( Ropivacaine, Sufentanil, Parecoxib Sodium, Ondansetron, Dexmedetomidine, Pantoprazole, Lidocaine, etc.) or allergies to artificial colloids ( Polygeline).

Design outcomes

Primary

MeasureTime frame
Postoperative hospital stay;

Secondary

MeasureTime frame
Dietary Intake;NPO duration;Time to first bowel movement;Correlation between postoperative nutrition consultation rate and arm strength at discharge;Adverse outcome rate;

Countries

China

Contacts

Public ContactTian Jinshan

Affiliated hospital of chengdu university

1102751775@qq.com+86 158 0280 6460

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026